NCT04016974View on ClinicalTrials.gov

A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 8, 2019

Primary Completion Date

January 23, 2021

Study Completion Date

February 26, 2021

Conditions
Healthy VolunteersDiabetes Mellitus, Type 2
Interventions
DRUG

Oral semaglutide

Semaglutide tablets once daily as follows: 3 mg for the first treatment period (day 1-28), followed by 7 mg in the second treatment period (day 29-56), followed by 14 mg in the third treatment period (day 57-84)

DRUG

Placebo

Placebo tablets once daily throughout the treatment period (day 1 to 84)

Trial Locations (1)

100730

Beijing Hospital-phase I, Beijing

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY